Dyskeratosis congenita (DC) is a genetic multisystem disorder with frequent involvement of the bone marrow. Haematopoietic stem cell transplantation (HSCT) is the only definitive cure to restore haematopoiesis, even though it cannot correct other organ dysfunctions. We collected data on the outcome of HSCT in the largest cohort of DC (n = 94) patients ever studied. Overall survival (OS) and event-free survival (EFS) at 3 years after HSCT were 66% and 62%, respectively. Multivariate analysis showed better outcomes in patients aged less than 20 years and in patients transplanted from a matched, rather than a mismatched, donor. OS and EFS curves tended to decline over time. Early lethal events were infections, whereas organ damage and secondary malignancies appeared afterwards, even a decade after HSCT. A non-myeloablative conditioning regimen appeared to be most advisable. Organ impairment present before HSCT seemed to favour the development of chronic graft-versus-host disease and T-B immune deficiency appeared to enhance pulmonary fibrosis. According to the present data, HSCT in DC is indicated in cases of progressive marrow failure, whereas in patients with pre-existing organ damage, this should be carefully evaluated. Further efforts to investigate treatment alternatives to HSCT should be encouraged.
Dyskeratosis congenita (DC), initially described as a dermatological disease because of the commonly seen triad of nail dystrophy, skin pigment modifications and oral leucoplakia, (Jansen, 1951) has now become recognized as a multisystem disorder due to the possible concomitant presence of bone marrow failure, pulmonary fibrosis, liver abnormalities, neurological, gastrointestinal, ocular impairment and cancer predisposition (Bryan & Nixon, 1965; Knight et al, 1998) .The causative mechanism of the disease is abnormal telomere shortening due to a defect in one of the genes encoding the telomerase-shelterin complex (DKC1, TERC, TERT, NHP2, NOP10, TCAB1, TPP1, TINF2, ACD, POT1, NAF1, STN1, CTC1, RTEL1 and PARN) (Calado & Young,2009; Nelson & Bertuch, 2012; Savage & Dufour, 2017) , observed in about 60-70% of patients, although the genetic lesion remains unidentified in approximately 30-40% of subjects (Mason & Bessler, 2011). Inheritance has been described as autosomal dominant, autosomal recessive or X-linked (Ballew & Savage, 2013) . Bone marrow failure is the main cause of death, although pulmonary fibrosis, hepatic cirrhosis and cancer significantly contribute to the morbidity and mortality (Parry et al, 2011; Ballew & Savage, 2013) . Targeted therapies for DC do not exist; androgens have shown some effect on haematopoiesis (Islam et al, 2013; Khincha et al, 2014) , telomere attrition and, possibly, lung function (Townsley et al, 2016) . Haematopoietic stem cell transplantation (HSCT) is the only definitive treatment to restore bone marrow function, even though it does not correct other abnormalities. Currently available data on the overall survival (OS) of transplanted DC patients and post-transplant complications have been derived from small series of patients (Alter et al, 2009; Giri et al, 2011; Gadalla et al, 2013; Barbaro & Vedi, 2016; Elamahadi et al, 2016) . In the present study, we aimed to evaluate the outcome of HSCT and post-transplant complications in a large cohort of patients affected by DC. To this end, information was acquired on 94 patients reported in the databases of the Severe Aplastic Anaemia Working Party (SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT), the European Working Group of Myelodysplastic Syndrome of Childhood (EWOG-MDS) and from a single US centre. The possibility to obtain data from such a large number of patients offers a unique opportunity to evaluate the outcomes of HSCT in a rare disease like DC.
Patients and methods

Origin of the data
This was a retrospective multicentre study performed via data collection using the databases of the SAAWP of the EBMT, EWOG-MDS and of the Pediatric Hemato-Oncology Center at the University of Minnesota, MN, USA. Each registry consecutively collects data on transplants [patient demographics, time and type of transplantation, source of stem cells, type of conditioning regimen, rates and severity of graft-versus-host disease (GvHD)] and on the follow-up. Specific items regarding DC and disease status before HSCT were asked using a dedicated questionnaire. All patients or legal guardians provided informed consent according to the Declaration of Helsinki.
Inclusion criteria, and primary end-points
Patients diagnosed with DC who received a first allogeneic transplant in the years between 1979 and 2015 and whose data were collected by the above-mentioned entities were considered eligible for the study. The indication for transplant was progressive bone marrow failure with pending or overt transfusion dependence. Diagnosis of DC was made on the basis of clinical features and, whenever available, genetic testing. OS and event-free survival (EFS) were the primary endpoints of the study. The effect of age, gender, calendar period, donor type, source of stem cells and conditioning regimen on OS and on EFS was also analysed.
Definitions
OS was calculated from the date of HSCT to the date of death or last follow-up. EFS was calculated from time of transplant to the first event: graft failure, loss of graft, second transplant, late tumours, death or last follow-up.
Engraftment was defined as the achievement of an absolute neutrophil count (ANC) ≥0Á5 9 10 9 /l for at least three consecutive days. Primary graft failure was defined as the ANC never reaching 0Á5 9 10 9 /l. Secondary graft failure was defined as an ANC of 0Á5 9 10 9 /l for at least three consecutive days, subsequently decreasing to a lower level. Acute and chronic GvHD and GvHD severity were defined according to published criteria (Shulman et al, 1980; Przepiorka et al, 1995) . Organ damage was defined as a chronic disorder occurring during follow-up and included pulmonary fibrosis, interstitial pneumonia, chronic lung diseases other than fibrosis or interstitial pneumonia, gastrointestinal stenosis and liver cirrhosis. Myelodysplastic syndrome (MDS) and acute leukaemia (AL) were defined according to the recently updated classification (Arber et al, 2016) . Secondary malignancies were reported as events occurring at any time after HSCT.
None of the adopted regimen fully matched the criteria for a myeloablative conditioning regimen (MAC) as reported in the literature (Giralt et al, 2009) . Therefore, all received a non-myeloablative conditioning regimen (NMAC) as recommended (Barbaro & Vedi 2016; Dietz et al, 2011) . Given the potential detrimental effect of irradiation and alkylating agents (AA) on DC subjects, for the purposes of this study, we subdivided NMACs in two groups (i) use of one AA in any of the combination (i.e. fludarabine + cyclophosphamide or fludarabine + melphalan) or use of radiotherapy (RT) alone, and (ii) use of ≥2 AA or of one AA in combination with RT (i.e. busulfan + cyclophosphamide and RT + fludarabine + cyclophosphamide) ( Table I) .
Statistical methods
OS and EFS probabilities were estimated and compared by applying standard methods of survival analysis (Kaplan-Meier estimator, Log Rank test and Cox regression). The selection of variables for the Cox regression was based on both clinical knowledge and on the assessment of significance in the univariate analysis; the model was checked for relevant departures from the hypothesis of proportional hazards. Causes of death and the occurrence of acute and chronic GvHD were analysed in a competing risks framework, applying the crude cumulative incidence estimator and the Gray test for comparisons. Competing risks for GvHD were graft failure and death. The distinction between acute and chronic GvHD was based on the time threshold of 100 days post-transplant, thus only patients surviving more than 100 days after HSCT were considered to be at risk of chronic GvHD (cGvHD); conversely, acute GvHD (aGvHD) was analysed up to 100 days after transplantation. All tests for the association between time-to-event endpoints with prognostic factors were mainly restricted to the first 3 years after transplantation, due to lack of long-term followup in the subgroups. For the comparison of characteristics between groups, standard non-parametric tests were applied (chi-squared or Fisher's exact test for categorical variables, the Mann-Whitney/Kruskal-Wallis test for continuous variables [software: SPSS v. 23 (IBM Corp. Armonk, NY, USA) and R studio v. 1.0.153(Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org)]. P values <0Á05 were considered statistically significant.
Results
Characteristics of the cohort
Ninety-four patients (69 males, 73% and 25 females, 27%) affected with DC were given an allogeneic HSCT between 1979 and 2015 from a human leucocyte antigen (HLA) matched related donor, (24%), an HLA-matched unrelated donor (51%) or from a mismatched donor (25%) and were included in the present study. The median age at diagnosis was 5Á8 years (range 0-33Á5 years), while the median time between diagnosis and HSCT was 18 months (range 0Á62-304 months). The median follow-up of the whole cohort was 43 months (range 2Á9-209 months). Age at transplant was less than 20 years in 81% and greater than 20 years in 19% of the cohort.
Fifteen patients were transplanted before 2000, whereas the remaining 79 were transplanted after 2000. The stem cell source was bone marrow (BM) in 63% of patients, peripheral blood (PB) in 24% and cord blood (CB) in 13% of cases. The characteristics of the patients are shown in Table I .
All patients underwent a NMAC-adopted regimen according to the literature definition (Giralt et al, 2009) . Thirty-five patients (49%) were exposed to irradiation alone or up to one AA, whereas the remaining 37 (51%) patients received RT plus one AA or two AA as part of their preparative regimen (Table I ). The most frequent drug combinations were cyclophosphamide + fludarabine (36%), followed by RT plus cyclophosphamide and fludarabine (35%). Ninety-three percent of patients received a ciclosporin-based GvHD prophylaxis regimen. Serotherapy consisted of alemtuzumab and/or anti-thymocyte globulin (rabbit or horse) ( Table I ).
Disease status before HSCT
All patients had marrow failure at transplant. For some of the pre-HSCT items, the data set was incomplete. Myelodysplasia before HSCT was documented in 8/55 patients. Data on non-haematological features were available in less than 50% of cases and consisted of: (i) B cell and/or T cell immunodeficiency (38%), (ii) severe enteropathy/cirrhosis/ gastrointestinal (GI) stenosis (11%) and (iii) lung fibrosis (7%). The type of mutation was available in 36% of patients. The most frequent was TINF2 (47%), followed by DKC1 (26%) and TERC/TERT (24%) ( Table I) .
Engraftment and GvHD
The overall probability of graft failure was 17% (5% for primary and 12% for secondary). Eleven patients received a second transplant and three of them were still alive at the last follow-up. Eight patients died of infection or graft failure, or both in 75% of cases. The cumulative incidence of aGvHD (grade II-IV) was 18% (95% confidence interval [CI] 10-26%). The cumulative incidence of cGvHD (limited in 30% and extensive in 70% of cases) was 31% (95% CI 18-44%) at 12 months after HSCT and 35% (95% CI 22-49%) at 36 months after HSCT. Chronic GvHD occurred significantly more frequently in patients who had pre-transplant organ damage (51%; 95% CI 24-78%) than in subjects without any extra-haematological features (13Á2%; 95% CI 0-30Á5%; P = 0Á038). The use of alemtuzumab vs. anti-thymocyte globulin (ATG) for GvHD prophylaxis resulted in a trend towards a lower occurrence of cGvHD (P = 0Á052).
Overall survival and event-free survival
The three-and five-year probability of OS was 66% (95% CI 56-77%) and 59% (95% CI 47-71%) respectively (Fig 1A) . Thirty-nine patients died, for a crude mortality rate of 41%. The causes of death were infection (43%), organ damage (lung and liver/GI) (25%), GvHD (8%), rejection/graft failure (8%), secondary malignancy (8%) and others (8%). There seemed to be a characteristic sequence of the causes of deaths over time. The cumulative incidence of deaths due to infections increased soon after HSCT and stabilized to 19% (95% CI 10-27%) at 5 years. Organ failure, which was virtually absent after HSCT, appeared 36 months after HSCT and reached a cumulative incidence of 11% (95% CI 10-27%) after 5 years and increased to 25% (95% CI 10-40%) at 10 years after transplantation. Not surprisingly, solid tumours first appeared 5 years after HSCT, and reached a plateau 10 years after transplantation with a cumulative incidence of 7Á5% (95% CI 0-18%) (Fig 2) .
When mortality was analysed by donor type, deaths occurred earlier (within the first 15 months) in subjects transplanted from an alternative donor (main cause was infection in 70% of cases) than in patients who received a matched sibling transplant (main causes were GvHD in 34% followed by infections, organ damage and secondary malignancy in 22% equally distributed). No correlation between causes of deaths and cell source were observed.
The three-year OS was better in subjects aged less than 20 years at HSCT (72% vs. 43%; P = 0Á018) (Fig 1) . HSCT outcome was not different by patient gender, interval between diagnosis and HSCT or year of HSCT (Table II) .
HSCTs performed with HLA-matched donors (related or unrelated) showed a trend towards a better OS than those performed with HLA-mismatched donors (73% vs. 46%; P = 0Á069) (Fig 1) . OS appeared superior with BM and PB (68% and 72%, respectively) versus CB cells (49%). However, this comparison was influenced by the small numbers of patients who received CB (Table II) .
The three-year OS of those subjects who received up to one AA without RT or RT without any AA as for their preparative regimen, was not significantly different from that in patients who were exposed to one AA plus RT or to ≥2 AA(67% vs. 62%; P = 0Á926).
The EFS probability of the whole cohort was 62% (95% CI 50-73%) at 3 years and 51% (95% CI 37-64%) at 5 years ( Fig 1B) .
In the population for who data was available, 36% (19/53) developed further organ damage (defined as a worsening of a pre-existing condition of the disease or a new pathological manifestation) during/after HSCT. Lung damage affected all patients but one, and was irreversible in 63% of cases. The median time to death caused by infection was shorter (0Á79 months; range 0Á46-111Á2 months) than that due to organ failure (median 27 months; range 0Á99-61Á59). Organ failure existing prior to transplantation had a significantly negative impact on survival (61% of deaths in subjects with organ damage vs. 23% in those without organ impairment; P = 0Á014), whereas the presence of T/B deficiency was associated with a trend towards an increased risk of pulmonary fibrosis (50% in subjects with T/B deficiency vs. 5% in those without any T/B deficiency; P = 0Á06). In the univariate analysis, the three-year EFS after transplantation was significantly better in patients transplanted from HLA-matched (related and unrelated, 69%) compared to HLA-mismatched donors (40%) (P = 0Á04) (Fig 1B) . Similar to the OS, the three-year EFS was higher in patients transplanted before the age of 20 years rather than after 20 years of age (66% vs. 42%, respectively), although this difference was of borderline significance (P = 0Á08).
The three-year EFS probability was not significantly different between patients whose conditioning regimen included RT without any AA or up to one AA versus those who received RT + one AA or ≥2 AA (56% vs. 69%: P = 0Á152).
In the multivariate analysis, age older than 20 years at HSCT and the use of a mismatched donor were confirmed to be significantly associated with a worse prognosis (Table III) .
Five cases of malignancies occurred: one each of breast cancer, epithelial haemangioendothelioma, Hodgkin lymphoma, non-Hodgkin lymphoma and solid tumour. This was the cause of death in three subjects, at 5, 10 and 11Á5 years after HSCT. Tumours occurred in the remaining two patients at 0Á6 and 1Á75 years after HSCT, respectively and they were alive at the last follow-up (2Á5 and 4Á5 years from HSCT).
Discussion
This is the largest study ever conducted on HSCT in DC. It shows that three-and five-year OS and EFS were 66%, 59%, 62% and 51%, respectively and that the crude mortality rate was 41%. The latter was lower than that shown in two previous studies (59% and 46%; Gadalla et al, 2013; Alter et al, 2009; respectively) , whereas the OS and EFS were in line with recent reviews (Barbaro & Vedi, 2016; Elamahadi et al, 2016) . Factors that, in the multivariate analysis, positively affected the outcome were age at HSCT <20 years and the use of a matched donor (either related or unrelated). As a lateral issue, it has to be noted that sibling donors need to be studied for telomere disease because a possible incomplete penetrance of the disease may attenuate the phenotype.
The cumulative incidence of cGvHD was 31% and 35%, respectively, at 1 and 3 years after transplant and was negatively influenced by pre-existing organ failure. Given that it may be difficult to discriminate between cGvHD and skin, GI, liver and lung involvement typical of DC, these high cGvHD rates may be over-estimated. Nevertheless, given the negative effects of GvHD on OS but also on the quality of life of survivors, efforts are required to reduce its occurrence. In this respect, alemtuzumab seemed to provide an advantage over ATG in reducing GvHD and might be a helpful tool. The OS and EFS curves showed a continuous decline over time that, in our study, was sustained by three main causes, in part overlapping and in part operating sequentially. Infections played an early role; secondary malignancies had an effect later and organ damage progressively appeared after infections.
The organ damage in DC, due to the inability to repair DNA and to renew tissues, is a limiting factor for a successful HSCT procedure. Our data set was. to some extent. incomplete regarding overall extra-haematological impairment before transplant. Nevertheless, looking at the subpopulation for whom data was available, pre-existing organ failure favoured the development of cGvHD and contributed, similarly to other studies, to late mortality (Peffault de Latour et al, 2013; Slack et al, 2018) . T/B lymphocyte deficiency might be an adjuvant element to the development of pulmonary fibrosis. Moreover, as recently confirmed in a large cohort, the cumulative incidence of secondary cancer in young age is strikingly increased in DC patients who underwent HSCT when compared with who did not, thus raising again a crucial dilemma on HSCT indication (Alter et al, 2018) .
Overall these findings underline that HSCT in DC may be indicated only if bone marrow failure is otherwise unmanageable and if non-relevant extra-haematological impairment is present. This suggests that organ status should be carefully evaluated during the decision-making process regarding performing HSCT or not, with a special focus on lung status, as it may increase the risk of GvHD and worsen survival (Barbaro & Vedi, 2016) . HSCT in DC should not be indicated as a pre-emptive measure. Indeed, careful bone marrow surveillance and a watchful policy, found to be successful in studies on other constitutional DNA repair marrow failure syndromes, such as Fanconi anaemia (Svahn et al, 2016) , seem to be advisable.
As for the conditioning regimen, given that all patients received a NMAC according to the literature definition (Giralt et al, 2009) we could not address the difference between MAC and NMAC. Nevertheless, within the framework of NMAC, the use of a combination of one AA plus RT or exposure to two AA vs RT alone or one AA, seem not to have different impact on OS and EFS. Given the higher risk of tissue damage and secondary malignancies, inherent in DC patients (Savage & Dufour 2017) and the preparative regimen being comparable, it may be advisable to adopt combinations such as fludarabine plus cyclophosphamide, used in a relevant proportion of our patients and also found to be effective in other studies (Vuong et al, 2010; Nishio et al, 2011; Ayas et al, 2013) . CI, confidence interval; EFS, event-free survival; HLA, human leucocyte antigen; HR, hazard ratio; OS, overall survival. *Given the non-relevant difference between matched related and matched unrelated donors in the univariate analysis, these two categories were combined together into the matched category in the multivariate analysis.
This study has some limitations, mainly related to its retrospective nature and to the incomplete data set for some items. These limits, that are indeed inherent to all registry studies to some extent, might preclude more robust conclusions regarding some end points. The main strengths are the magnitude of the study, an issue particularly important in rare diseases like DC where prospective trials are extremely difficult to run, and the streamlined study design that still enabled us to address important steps in the decision-making process regarding HSCT in DC.
In conclusion, HSCT might be a treatment option in subjects affected by DC and bone marrow failure, but it is associated with a high risk of early and late mortality due to infections, organ damage and secondary malignancies. This suggests that the indication for HSCT in DC patients with marrow failure has to be established on an individual basis after a thorough evaluation of lung and non-haematological organ damage.
